Crohn Disease
Conditions
Keywords
Crohn Disease, Regulatory T-cells, Infliximab
Brief summary
Aim: the main aim of this study is to investigate if immune cells (regulatory T-cells, Th17 cells and other immune cell types) or biomarkers can be used to predict the response or lack of response to treatment with Infliximab. If so, characteristics of the immune cells may also unveil the mechanisms behind lack of response to Infliximab. Design: a prospective, observational study with three arms. In the treatment group, 35 patients with Crohn's disease about to start Infliximab-treatment are recruited. They have blood samples drawn at day 1 before first treatment, after 6 week, and again after 22 weeks of treatment. 12 healthy volunteers serve as a control group. Controls are only investigated once. All treatment and follow-up are according to national guidelines, and data from this study is not used by the clinicians. Methods: the number of regulatory T-cells and pro-inflammatory T-cells (Th17 cells) is investigated using flow cytometry. From plasma and serum samples, various proteins (biomarkers), such as transforming growth factor beta (TGF-beta) and tumour necrosis factor alpha (TNF-alpha), are measured using immunoassays. Patient data (demographics and medical history) are extracted from various registries.
Detailed description
Primary analyses: patient response to Infliximab treatment is quantified using Harvey Bradshaw Index, and the response is then related to the number of regulatory T-cells, Th17 cells, and biomarker levels at baseline. The exact cut-off for response vs. non-respons will be determined and validated once all data is collected by an assessor blinded for the flow cytometry results and biomarker levels. Plan for missing data: for patients with missing Harvey Bradshaw Index, we will first try to re-create the score using the patient records (information on well-being, abdominal pain, diarrhea, fistulae/abscesses, and extra-intestinal Crohn manifestations). If this is not possible, an experienced clinician will rate the patient's Infliximab response based on all available patient record data, but blinded for flow cytometry results and biomarker levels.
Interventions
DRUGInfliximab
The patients are included in the study when the decision to treat with Infliximab is already made. This study is observational, and all treatment and clinical follow-up are according to national guidelines.
Sponsors
Hvidovre University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Infliximab group Inclusion Criteria: * Crohn's Disease * Starting Infliximab treatment * Patient at the gastrointestinal department at Hvidovre Hospital or Køge Sygehus * Can understand and write Danish * European ancestry
Exclusion criteria
* Not able to consent in an ethical manner (e.g. severe mental illness) * Significant co-morbidity (e.g. cancer, HIV) * Other immunological disease (e.g. psoriasis) * Current treatment with biological agents Healthy controls Inclusion Criteria: * No current disease * No daily drug use * Can understand and write Danish * European ancestry
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in number of regulatory T-cells at 6 weeks | Baseline, 6 weeks (plus/minus 1 week) | The number of regulatory T-cells is measured in fresh blood by flow cytometry. |
| Change from baseline in number of regulatory T-cells at 22 weeks | Baseline, 22 weeks (plus/minus 1 week) | The number of regulatory T-cells is measured in fresh blood by flow cytometry. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in CD161 expression at 22 weeks | Baseline, 22 weeks (plus/minus 1 week) | CD161 is a Th17-marker, measured by flow cytometry of fresh blood samples. |
| Change from baseline in cytokine levels at 6 weeks | Baseline, 6 weeks (plus/minus 1 week) | We will measure IFN-gamma, IL-4, IL-6, IL-7, IL-10, IL-15, IL-17, and TNF-alpha by Luminex. TGF-beta, suPAR, and IL-15 will be measured by ELISA. |
| Change from baseline in Harvey Bradshaw Index at 6 weeks | Baseline, 6 weeks (plus/minus 1 week) | Harvey Bradshaw Index is a measure of Crohn's Disease severity. |
| Change from baseline in Harvey Bradshaw Index at 22 weeks | Baseline, 22 weeks (plus/minus 1 week) | Harvey Bradshaw Index is a measure of Crohn's Disease severity. |
| Change from baseline in cytokine levels at 22 weeks | Baseline, 22 weeks (plus/minus 1 week) | We will measure IFN-gamma, IL-4, IL-6, IL-7, IL-10, IL-15, IL-17, and TNF-alpha by Luminex. TGF-beta, suPAR, and IL-15 will be measured by ELISA. |
| Change from baseline in CD161 expression at 6 weeks | Baseline, 6 weeks (plus/minus 1 week) | Cluster of differentiation 161 (CD161) is a T helper 17 cell (Th17)-marker, measured by flow cytometry of fresh blood samples. |
Countries
Denmark
Outcome results
None listed